A Phase Ii Study Of Sorafenib In Malignant Mesothelioma With Pharmacodynamic Imaging Using (18)Fdg-Pet

S. Irshad,Sanjay Popat,Riyaz Shah, S. Burbridge,Rohit Lal,Loic Lang-Lazdunski,Zaid Viney,P. Marsden,Sally Barrington,James Spicer

JOURNAL OF CLINICAL ONCOLOGY（2010）

引用 7|浏览11

暂无评分

摘要

7038 Background: Sorafenib inhibits tyrosine kinases including receptors for VEGF, which are present at particularly high circulating levels in mesothelioma patients. Antibodies to VEGF, VEGFR1 and...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要